Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15386 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Xuemei Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, RD. Minjiang, Dist. Kecheng…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pleural Neoplasms. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hai Yan Science Foundation of Harbin Medical University Cancer Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
This study aimed to investigate the effects of immune checkpoint inhibitors (ICIs) versus chemotherapy on the prognosis of real‐world diffuse pleural mesothelioma patients in China.
Methods
Clinical data of 90 patients with diffuse pleural mesothelioma from 2019 to 2022 were collected from Harbin Medical University Cancer Hospital. Patients were divided into two groups: the ICIs‐treated group ( n = 46) and the chemotherapy‐only group ( n = 44). The efficacy and safety of immunotherapy relative to chemotherapy at different treatment stages were explored.
Results
The median progression‐free survival (PFS) was 10.0 and 7.0 months, and the median overall survival (OS) was 24.7 and 15.8 months in the ICIs‐treated group and the chemotherapy group, respectively. The ICIs‐treated group showed an 11% increase in objective response rate (ORR) (52.2% vs. 41.0%) and an 8.0% increase in disease control rate (DCR) (78.3% vs. 70.0%) compared to the chemotherapy group. The Kaplan–Meier curves demonstrated significant PFS (HR: 0.61; 95% CI: 0.38–0.98; p = 0.038) and OS (HR: 0.47; 95% CI: 0.26–0.86; p = 0.011) benefits of receiving immunotherapy over chemotherapy alone. Subgroup analysis according to treatment timing showed the same trend.
Conclusion
In patients with nonsurgical diffuse pleural mesothelioma, immunotherapy achieved better survival benefits compared to chemotherapy in both first‐ and second‐/third‐line treatments. The early addition of immunotherapy improved survival in patients with nonsurgical diffuse pleural mesothelioma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, RD. Minjiang, Dist. Kecheng, Quzhou, Zhejiang, China.
- Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
- Department of Thoracic Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, China.
ORCID-Profile: Qingwei Li
Förderung
- Hai Yan Science Foundation of Harbin Medical University Cancer Hospital
Zitieren
APA
Zhang, X., Chang, L., Ma, Q., Zhang, Q., Xu, W., & Li, Q. (2024). Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15386
Vancouver
Zhang X, Chang L, Ma Q, Zhang Q, Xu W, Li Q. Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15386
BibTeX
@article{Zhang2024,
author = {Zhang, Xuemei and Chang, Lele and Ma, Qian and Zhang, Qian and Xu, Wansu and Li, Qingwei},
title = {Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15386}
}
EUVIMED